Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CILAZAPRIL

All products: not a benefit

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Lisinopril (Prinivil): general benefit, Not a benefit
  • Perindopril erbumine (Coversyl): general benefit

3 more in the class list below

Inhibace · DIN 01911473 · 2.5mg · tablet

Listed, not a benefitDormant since 2021-06-16 · checked 2026-09-02 · What does dormant mean?
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Inhibace · DIN 01911473 Manufacturer: Hoffmann-La Roche Limited; listing date 1996-10-01 Daily cost (source): $0.4295 Health Canada: Dormant since 2021-06-16 · brand INHIBACE · ATC C09AA08 CILAZAPRIL · form Tablet · route Oral · ingredients CILAZAPRIL (CILAZAPRIL MONOHYDRATE) 2.5 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Inhibace: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13835 · Verify on the e-Formulary ↗ (DIN 01911473)

Source record
DIN 01911473: Inhibace Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y Item: 240800190; group id 318; item number 0706; lccId None; manufacturer id HLR Source form: Tab; strength: 2.5mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01911473 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=13835
Interchangeable products
Apo-Cilazapril · DIN 02291142 · $0.4295 Mylan-Cilazapril · DIN 02283786 · $0.4295
Shortage status: active shortage (reported 2018-11-26, last updated 2019-02-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01911473
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-06-16 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

LISINOPRIL

· 45 products · Listed, not a benefit (1), General benefit (44) · strengths: 5mg, 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE INHIBACE (cilazapril) is indicated in the treatment of mild to moderate essential hypertension. INHIBACE may be used alone or in combination with thiazide-type diuretics. INHIBACE is also indicated in the treatment of congestive heart failure as an adjunctive therapy with digitalis and/or diuretics. In using INHIBACE consideration should be given to the risk of angioedema (see WARNINGS AND PRECAUTIONS). Hypertension INHIBACE should normally be used in those patients in whom treatment with a diuretic or a beta-blocker was found ineffective or has been associated with unacceptable adverse effects. INHIBACE can also be tried as an initial agent in those patients in whom use of diuretics and/or beta-blockers is contraindicated or in patients with medical conditions in which these drugs frequently cause serious adverse effects. The safety and efficacy of INHIBACE in renovascular hypertension has not been established and therefore, its use in this condition is not recommended. Page 3 of 51 The safety and efficacy of concomitant use of INHIBACE with antihyperte… https://pdf.hres.ca/dpd_pm/00056636.PDF PM date: June 2, 2020 Source product: INHIBACE; DIN 01911481; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Inhibace · DIN 01911473 Shortage status: active shortage (reported 2018-11-26, last updated 2019-02-19) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01911473

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Other review policies

For Inhibace: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026